Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314299 | 0.95 | SLC18A3 (0.67) | SLC18A3CHRM4PRMT5WDR77SIGMAR1 | |
| SCHEMBL313776 | 0.88 | PRMT5 (0.64) | SLC18A3CHRM4PRMT5WDR77SIGMAR1 | |
| Formic Acid SCHEMBL314781 | 0.81 | HTR1A (0.52) | SIGMAR1ALDH1A1HRH3DRD2 | |
| SCHEMBL8922008 | 0.77 | CHRM4 (0.59) | SLC18A3CHRM4PRMT5WDR77ALDH1A1 | |
| SCHEMBL314343 | 0.76 | MC4R (0.60) | CHRM4SIGMAR1ALDH1A1 | |
| SCHEMBL313962 | 0.76 | HTR1A (0.57) | SIGMAR1ALDH1A1HRH3DRD2 | |
| SCHEMBL3718111 | 0.75 | ALDH1A1 (0.56) | CHRM4PRMT5WDR77SIGMAR1ALDH1A1 | |
| SCHEMBL8262849 | 0.75 | ALDH1A1 (0.42) | ALDH1A1HRH3 | |
| SCHEMBL4002382 | 0.75 | CHRM4 (0.58) | SLC18A3CHRM4PRMT5WDR77SIGMAR1 | |
| SCHEMBL21159622 | 0.73 | BRD4 (0.61) | SLC18A3CHRM4ALDH1A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| CN-102015668-A | Piperazine derivatives and their use as leptin receptor modulators | ASTRAZENECA AB PUBL | 2011-04-13 | — | — | CN | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | SLC18A3 4502/4885CHRM4 1879/4885PRMT5 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.